Press Releases

 Apr 18, 2023, 07:30 ET  –  International Journal of Molecular Sciences manuscript demonstrates robust pre-clinical data in two retinal disease models –  Studies further demonstrate broad utility of melanocortin agonists in treating inflammatory conditions, especially in the eye CRANBURY, N.J., April 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that […]

 Mar 02, 2023, 07:30 ET  Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J., March 2, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in

 Feb 28, 2023, 07:30 ET  CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled “Use of Bremelanotide in

 Feb 15, 2023, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced First Patient Dosed Planned Interim Analysis Targeted for First Half Calendar Year 2023 Topline Results Currently Expected

 Feb 10, 2023, 07:30 ET  CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

 Jan 19, 2023, 07:30 ET  –  BREAKOUT Study is Palatin’s third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists –  Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J., Jan. 19, 2023

 Jan 18, 2023, 07:30 ET  Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J., Jan. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7

 Jan 10, 2023, 07:30 ET  –  Collaboration with The William Harvey Research Institute and Queen Mary University of London –  PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J., Jan. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers

 Jan 05, 2023, 07:30 ET  15.4% increase in net product revenue over the prior quarter 1,290% increase over the comparable quarter in 2021 11.5% increase in prescriptions dispensed over the prior quarter Increased 134% over the comparable quarter in 2021 CRANBURY, N.J., January 5, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical

 Nov 14, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Net Product Revenue Increased 13% and Prescriptions Dispensed Increased 17%, Over the Prior Quarter Prescription Refills Exceed 50%